Related Experiment Video
Updated: Jan 23, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway
Fulu Dong1,2, Ping Yang3, Rui Wang1,2
1Laboratory of Nuclear Receptors and Cancer Research, Basic Medical Research Center, School of Medicine, Nantong University, Nantong, Jiangsu, China.
Background:
The increasing incidence of prostate cancer (PCa) indicates an urgent need for the development of new effective drugs in PCa therapy. Triptonide has been reported to have a strong inhibition activity in cancers through screening of Chinese herbal medicine. This study aims to investigate the effects of triptonide on anti-PCa activity and its mechanisms.
Methods:
Three human advanced PCa cell lines PC3, DU145, and LNCap, and a human normal prostate epithelial cell line RWPE were treated with a range (0, 1.25, 2.5, 5, 10, 20, 40, 80, 160, and 320 nM) of triptonide concentrations for 72 hours respectively. Then, cell viability was assessed by cell counting kit-8. PCa cells were treated with different doses (0-20 nM) of triptonide for 72 hours. Cell cycle and apoptosis were assessed by flow cytometry assays. Nude mice bearing human PCa xenografts were intraperitoneally injected daily with either triptonide (10 mg/kg/d) or phosphate-buffered saline as a control for 35 days. RNA-sequencing (RNA-seq) was performed by an Illumina Hiseq Sequencing platform and confirmed by a real-time polymerase chain reaction. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis, and ingenuity pathway analysis were used to analyze RNA-seq results.
Results:
Triptonide effectively inhibits the proliferation of human PCa cells PC3, DU145, and LNCap in vitro with their IC50 values as 11.961, 10.259, and 12.012 nM, respectively. Triptonide (10 mg/kg) potently inhibits the growth of PCa cell xenografts in vivo at an inhibition rate of over 97.95%. Treatment with triptonide (5 nM) significantly promotes cell apoptosis and retaining cell-cycle arrest in the G2/M phase. RNA-seq data revealed that total of 936 genes were upregulated or downregulated in triptonide treated. Moreover, the phosphorylation of mechanistic target of rapamycin (mTOR) and the downstream protein p70S6K were both inhibited, most obviously in PCa cells.
Conclusions:
Our findings suggest that triptonide can efficaciously suppress PCa growth in vitro and in vivo via inhibiting the phosphorylation of mTOR and the activities of related downstream signaling pathways.
Insights
Triptonide effectively inhibits prostate cancer (PCa) cell growth in vitro and in vivo. This study reveals triptonide suppresses PCa by inhibiting mTOR signaling pathways, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Prostate cancer (PCa) incidence is rising, necessitating novel therapeutic agents.
- Triptonide, identified from Chinese herbal medicine, shows potent anti-cancer activity.
- This research investigates triptonide's efficacy and mechanisms against PCa.
Purpose of the Study:
- To evaluate the anti-prostate cancer effects of triptonide in vitro and in vivo.
- To elucidate the molecular mechanisms underlying triptonide's anti-PCa activity.
- To explore triptonide as a potential therapeutic candidate for prostate cancer.
Main Methods:
- Human PCa cell lines (PC3, DU145, LNCap) and normal prostate cells (RWPE) were treated with varying triptonide concentrations.
- Cell viability, cell cycle, and apoptosis were assessed using cell counting kit-8 and flow cytometry.
- In vivo efficacy was evaluated in nude mice bearing PCa xenografts, followed by RNA-sequencing (RNA-seq) for mechanism elucidation.
Main Results:
- Triptonide demonstrated significant inhibition of PCa cell proliferation in vitro (IC50 values 10.259–12.012 nM).
- Triptonide potently inhibited PCa xenograft growth in vivo (>97.95% inhibition rate).
- Triptonide induced G2/M cell cycle arrest, promoted apoptosis, and downregulated mTOR phosphorylation and downstream signaling.
Conclusions:
- Triptonide exhibits significant anti-prostate cancer activity both in vitro and in vivo.
- The mechanism involves the inhibition of mechanistic target of rapamycin (mTOR) phosphorylation and related signaling pathways.
- Triptonide represents a promising therapeutic agent for prostate cancer treatment.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...